Όλο το DSpace

Πλοήγηση ανά Θέμα "lamivudine"

Αποτελέσματα 1-6 από 6

    • Association of antiviral therapy with reduced disease progression in chronic hepatitis b patients: Results from a nation-wide cohort study 

      Vourli G., Papatheodoridis G., Raptopoulou M., Dalekos G.N., Hounta A., Nikolopoulou G., Zouboulis-Vafeiadis I., Manesis E., Kitis G., Gogos C., Ketikoglou I., Hatzis G., Vasilialdis T., Karatapanis S., Mimidis K., Drakoulis C., Touloumi G., The Hepnet-Greece Study (2016)
      Background and Aims: Although effective treatment in terms of inducing virological and biochemical response for chronic hepatitis B (CHB) is available, its effect on the clinical course of the disease has not yet been ...

    • Hepatocellular carcinoma risk in HBeAg-negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort 

      Papatheodoridis, G. V.; Manolakopoulos, S.; Touloumi, G.; Nikolopoulou, G.; Raptopoulou-Gigi, M.; Gogos, C.; Vafiadis-Zouboulis, I.; Karamanolis, D.; Chouta, A.; Ilias, A.; Drakoulis, C.; Mimidis, K.; Ketikoglou, I.; Manesis, E.; Mela, M.; Hatzis, G.; Dalekos, G. N. (2015)
      Hepatocellular carcinoma (HCC) may still develop in chronic hepatitis B (CHB) patients treated with lamivudine. Whether HCC rates are comparable in patients treated with the current first-line antivirals remains uncertain. ...

    • Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B: Antiviral and immunological activity 

      Rigopoulou, E. I.; Suri, D.; Chokshi, S.; Mullerova, I.; Rice, S.; Tedder, R. S.; Williams, R.; Naoumov, N. V. (2005)
      Interleukin-12 (IL-12) is an immunomodulatory cytokine that promotes cellular immunity. Pre-clinical data suggest that IL-12 inhibits hepatitis B virus (HBV) replication by stimulating interferon-gamma (IFN-γ) production. ...

    • Management of severe acute to fulminant hepatitis B: to treat or not to treat or when to treat? 

      Tillmann, H. L.; Zachou, K.; Dalekos, G. N. (2012)
      Despite a decline in cases of acute hepatitis B and the low hepatitis B virus (HBV) chronicity rates in adults, still some patients progress to HBV-related fulminant liver failure. In this review, we discuss treatment ...

    • Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience 

      Tillmann, H. L.; Hadem, J.; Leifeld, L.; Zachou, K.; Canbay, A.; Eisenbach, C.; Graziadei, I.; Encke, J.; Schmidt, H.; Vogel, W.; Schneider, A.; Spengler, U.; Gerken, G.; Dalekos, G. N.; Wedemeyer, H.; Manns, M. P. (2006)
      Acute hepatitis B progresses to liver failure with the need of liver transplantation in about 1% of cases. We treated patients with severe acute or fulminant hepatitis B with lamivudine in an attempt to prevent hepatitis ...

    • The state of hepatitis B and C in the mediterranean and balkan countries: Report from a summit conference 

      Hatzakis, A.; Van Damme, P.; Alcorn, K.; Gore, C.; Benazzouz, M.; Berkane, S.; Buti, M.; Carballo, M.; Cortes Martins, H.; Deuffic-Burban, S.; Dominguez, A.; Donoghoe, M.; Elzouki, A. N.; Ben-Alaya Bouafif, N.; Esmat, G.; Esteban, R.; Fabri, M.; Fenton, K.; Goldberg, D.; Goulis, I.; Hadjichristodoulou, T.; Hatzigeorgiou, T.; Hamouda, O.; Hasurdjiev, S.; Hughes, S.; Kautz, A.; Malik, M.; Manolakopoulos, S.; Matičič, M.; Papatheodoridis, G.; Peck, R.; Peterle, A.; Potamitis, G.; Prati, D.; Roudot-Thoraval, F.; Reic, T.; Sharara, A.; Shennak, M.; Shiha, G.; Shouval, D.; Sočan, M.; Thomas, H.; Thursz, M.; Tosti, M.; Trépo, C.; Vince, A.; Vounou, E.; Wiessing, L.; Manns, M. (2013)
      The burden of disease due to chronic viral hepatitis constitutes a global threat. In many Balkan and Mediterranean countries, the disease burden due to viral hepatitis remains largely unrecognized, including in high-risk ...